NCT05694819 2026-04-08
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Phase 2 Completed
Clinical Trials
23 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT02799602 2025-12-04
ARASENS
Bayer
Phase 3 Completed
NCT05202301 2025-08-11
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT06013475 2025-06-12
DEAR-EXT
Bayer
Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT05612880 2025-01-09
Physical Function During ARSI Treatment
UNC Lineberger Comprehensive Cancer Center
Completed
NCT06498921 2024-10-24
BELBEQA
Bayer
Completed
NCT06204302 2024-04-09
ARENA
Bayer
Completed
NCT05362149 2024-03-20
DEAR
Bayer
Completed
NCT03383679 2022-11-21
START
UNICANCER
Phase 2 Completed
NCT02200614 2022-06-28
ARAMIS
Bayer
Phase 3 Completed
NCT01784757 2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03004534 2020-04-03
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Translational Research in Oncology
Phase EARLY_PHASE1 Completed
NCT03237416 2018-11-06
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Bayer
Phase 1 Completed
NCT01317641 2017-03-29
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed
NCT02671097 2016-09-08
Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate
Bayer
Phase 1 Completed